Early immune therapy may tame rare eye disease

NCT ID NCT03399175

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether starting strong immune-suppressing drugs early can help control Vogt-Koyanagi-Harada (VKH) disease, a rare condition that causes eye inflammation and vision loss. Researchers will treat 40 newly diagnosed patients with high-dose steroids and other immune-suppressing medicines, then track their eye health for at least a year using special tests. The goal is to see if early treatment can reduce disease activity and protect vision.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VOGT KOYANAGI HARADA DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Vogt-Koyanagi-Harada disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hospital das Clinicas HCFMUSP, Faculdade de Medicina Universidade de Sao Paulo

    RECRUITING

    São Paulo, São Paulo, 05403-000, Brazil

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••